During Wednesday’s Current trade, Shares of Cummins Inc. (NYSE:CMI), lost -1.13% to $129.97.
Cummins Inc. (CMI) declared that Dr. John Wall, Vice President — Chief Technical Officer, will be retiring after nearly 30 years with the Company. Wall has been at the center of many pivotal moments and initiatives in Cummins’ history over the past quarter century.
Jennifer Rumsey, Vice President of Engineering for Cummins’ Engine Business, will take Wall’s place. She is the first woman to serve as the Company’s top technical leader.
Cummins Inc. designs, manufactures, distributes, and services diesel and natural gas engines, and engine-related component products. It operates through four segments: Engine, Distribution, Components, and Power Generation. The Engine segment offers various diesel and natural gas powered engines under the Cummins and other customer brand names for the heavy-and medium-duty truck, bus, recreational vehicle, light-duty automotive, agricultural, construction, mining, marine, oil and gas, rail, and governmental equipment markets.
Shares of Servicemaster Global Holdings Inc (NYSE:SERV), declined -0.92% to $35.52, during its current trading session.
Servicemaster Global Holdings Inc (SERV) raised the number of directors serving on the Board from eight to nine and filled the vacancy created by such newly-created directorship by appointing Mark E. Tomkins. Mr. Tomkins will serve as a Class III Director, where his initial term will expire at the Company’s 2017 annual stockholders meeting. The Board determined, after considering all of the relevant facts and circumstances, that Mr. Tomkins is “independent” as defined under NYSE listing standards. The Board also determined that Mr. Tompkins is an “audit committee financial expert” as defined by SEC rules and is “financially literate” as defined under NYSE listing standards and designated him to serve as a member of the Audit Committee of the Board. In connection with Mr. Tomkins’ appointment, Sarah Kim resigned as member of the Audit Committee. As a result, the Company’s Audit Committee is now entirely comprised of independent directors.
ServiceMaster Global Holdings, Inc. provides residential and commercial services in the United States. It operates in three segments: Terminix, American Home Shield, and the Franchise Services Group. The Terminix segment offers termite and pest control services, counting termite remediation, annual termite inspection and prevention treatments with damage claim guarantees, periodic pest control services, insulation services, mosquito control, crawlspace encapsulation, and wildlife exclusion.
Signal Genetics Inc (NASDAQ:SGNL), during its Wednesday’s current trading session decreased -4.63% to $2.27.
Signal Genetics, Inc. (SGNL) a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that assist physicians make better-informed decisions concerning the care of their patients suffering from cancer, declared the signing of a Master Service Agreement (MSA) with a leading pharmaceutical company. Under the MSA, Signal’s proprietary MyPRS(R) genetic test will be run across multiple clinical trials in connection with the development of novel treatments for patients with multiple myeloma.
Signal and the pharmaceutical company have triggered the first of four studies as part of the MSA. Under the agreement, MyPRS(R) will assist inform patterns of response to novel therapy regimens with the aim of enabling physicians to better manage multiple myeloma patients based on their specific genetic profile.
Signal Genetics, Inc., a commercial stage molecular genetic diagnostic company, focuses on providing diagnostic services that assist physicians in decision making for the care of patients suffering from cancer. It offers Myeloma Prognostic Risk Signature (MyPRS) test, a microarray-based gene expression profile assay to test the presence of various groups of genes that predict low or high level risk of early relapse in patients suffering from multiple myeloma.
Finally, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), decreased -1.06%, to $138.31.
BioMarin Pharmaceutical Inc. (BMRN) recently declared the U.S. Food and Drug Administration (FDA) has accepted for review the submission of a New Drug Application (NDA) for drisapersen for the treatment of Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping, and the Prescription Drug User Fee Act (PDUFA) aim date for a decision is December 27, 2015. The FDA has granted drisapersen Priority Review status, which is designated to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists.
In the FDA’s filing communication, the Agency informed the company that it is presently planning to hold an advisory committee meeting to talk about the application. No date has been set for this meeting. Drisapersen formerly has been granted Orphan and Fast Track status, in addition to Breakthrough Therapy designations by the FDA. The U.S. filing is based on three randomized placebo-controlled trials and two long-term open-label studies of more than 300 patients in which some boys have been treated for more than three years.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products comprise Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
